Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Mr Rajit Mehta as Non- Executive Independent Director of the company w.e.f. July 27, 2026.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs held its Board meeting on April 30, 2026, approving multiple items including audited FY26 results showing revenue of INR 27,629 million (up 12% YoY) and net profit of INR 5,098 million. The Board recommended a final dividend of INR 4 per share, taking total dividend for FY26 to INR 20.5 per share. Key strategic decisions include acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited and incorporation of a wholly owned subsidiary in Dubai. Mr. Rajit Mehta has been re-appointed as Non-Executive Independent Director for 5 years from July 27, 2026, subject to shareholder approval at the ensuing AGM. The company also designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel and allotted 82,750 equity shares under the ESOP plan.
The appointment of Mr. Rajit Mehta as Independent Director ensures continuity in board governance. Strong financial performance with 12% revenue growth and increased dividend payout are positive signals for shareholders.